Abstract: Hepatocyte death caused by liver injury leads to the activation of myofibroblasts, which in turn secrete a large amount of extracellular matrix, resulting in liver fibrosis. Liver fibrosis is a key step in the progression of chronic liver disease to cirrhosis; however, there are currently few clinically recognized effective drugs for treating liver fibrosis. Therefore, it is very important to deeply understand the pathogenesis of liver fibrosis and to identify new therapeutic targets. This article reviews the research progress in pathogenesis of liver fibrosis and the related clinical therapeutic drugs, aiming to provide references for the prevention and treatment of liver fibrosis.